TABLE 4.
List of up/down regulated significant pathways derived from Reactome analysis (p-value < 0.05).
| Pathway name | Entities found | Entities Total | Entities ratio | Entities p-Value | Entities FDR |
| Upregulated proteins | |||||
| TYSND1 cleaves peroxisomal proteins | 1 | 7 | 0.001 | 8.42E-3 | 9.35E-2 |
| Platelet degranulation | 2 | 128 | 0.011 | 1.02E-2 | 9.35E-2 |
| Response to elevated platelet cytosolic Ca2 + | 2 | 133 | 0.011 | 1.09E-2 | 9.35E-2 |
| Beta-oxidation of very long chain fatty acids | 1 | 11 | 0.001 | 1.32E-2 | 9.35E-2 |
| HDL remodeling | 1 | 11 | 0.001 | 1.32E-2 | 9.35E-2 |
| Transport of organic anions | 1 | 12 | 0.001 | 1.44E-2 | 9.35E-2 |
| Caspase-mediated cleavage of cytoskeletal proteins | 1 | 12 | 0.001 | 1.44E-2 | 9.35E-2 |
| alpha-linolenic acid (ALA) metabolism | 1 | 13 | 0.001 | 1.56E-2 | 9.35E-2 |
| alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | 1 | 13 | 0.001 | 1.56E-2 | 9.35E-2 |
| p130Cas linkage to MAPK signaling for integrins | 1 | 15 | 0.001 | 1.8E-2 | 9.35E-2 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | 1 | 15 | 0.001 | 1.8E-2 | 9.35E-2 |
| Membrane binding and targeting of GAG proteins | 1 | 15 | 0.001 | 1.8E-2 | 9.35E-2 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | 1 | 15 | 0.001 | 1.8E-2 | 9.35E-2 |
| Heme biosynthesis | 1 | 15 | 0.001 | 1.8E-2 | 9.35E-2 |
| HCMV Late Events | 2 | 173 | 0.015 | 1.8E-2 | 9.35E-2 |
| Recycling of bile acids and salts | 1 | 16 | 0.001 | 1.92E-2 | 9.35E-2 |
| Heme degradation | 1 | 16 | 0.001 | 1.92E-2 | 9.35E-2 |
| MyD88 deficiency (TLR2/4) | 1 | 19 | 0.002 | 2.27E-2 | 9.35E-2 |
| IRAK4 deficiency (TLR2/4) | 1 | 20 | 0.002 | 2.39E-2 | 9.35E-2 |
| Regulation of TLR by endogenous ligand | 1 | 21 | 0.002 | 2.51E-2 | 9.35E-2 |
| Downregulated proteins | |||||
| Post-translational protein phosphorylation | 2 | 107 | 0.009 | 3.65E-3 | 6.7E-2 |
| Alternative complement activation | 1 | 5 | 0 | 4.31E-3 | 6.7E-2 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | 2 | 124 | 0.011 | 4.87E-3 | 6.7E-2 |
| Activation of C3 and C5 | 1 | 7 | 0.001 | 6.02E-3 | 6.7E-2 |
| Neutrophil degranulation | 3 | 480 | 0.041 | 6.85E-3 | 6.7E-2 |
| Type I hemidesmosome assembly | 1 | 11 | 0.001 | 9.45E-3 | 6.7E-2 |
| Caspase-mediated cleavage of cytoskeletal proteins | 1 | 12 | 0.001 | 1.03E-2 | 6.7E-2 |
| Retinoid cycle disease events | 1 | 13 | 0.001 | 1.12E-2 | 6.7E-2 |
| Diseases associated with visual transduction | 1 | 13 | 0.001 | 1.12E-2 | 6.7E-2 |
| Diseases of the neuronal system | 1 | 13 | 0.001 | 1.12E-2 | 6.7E-2 |
| Innate Immune System | 4 | 1,19 | 0.103 | 1.4E-2 | 7.02E-2 |
| The canonical retinoid cycle in rods (twilight vision) | 1 | 23 | 0.002 | 1.97E-2 | 7.93E-2 |
| Miscellaneous transport and binding events | 1 | 26 | 0.002 | 2.22E-2 | 7.93E-2 |
| Purinergic signaling in leishmaniasis infection | 1 | 27 | 0.002 | 2.31E-2 | 7.93E-2 |
| Cell recruitment (pro-inflammatory response) | 1 | 27 | 0.002 | 2.31E-2 | 7.93E-2 |
| Extracellular matrix organization | 2 | 301 | 0.026 | 2.64E-2 | 7.93E-2 |
| Transferrin endocytosis and recycling | 1 | 31 | 0.003 | 2.64E-2 | 7.93E-2 |
| Apoptotic cleavage of cellular proteins | 1 | 38 | 0.003 | 3.23E-2 | 8.8E-2 |
| Retinoid metabolism and transport | 1 | 44 | 0.004 | 3.73E-2 | 8.8E-2 |
| Metabolism of fat-soluble vitamins | 1 | 48 | 0.004 | 4.07E-2 | 8.8E-2 |